Giuseppe Procopio
Overview
Explore the profile of Giuseppe Procopio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
289
Citations
6653
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Albiges L, Gross-Goupil M, Barthelemy P, Bamias A, Bedke J, Bex A, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39924391
Background And Objective: Management of metastatic renal cell carcinoma (mRCC) remains complex despite clinical guidelines. The aim of this Delphi study was to achieve consensus among RCC experts on the...
2.
Brunelli C, Alfieri S, Zito E, Spelta M, Arba L, Lombi L, et al.
JMIR Cancer
. 2025 Jan;
11:e56625.
PMID: 39842002
Background: "Patient Voices" is a software developed to promote the systematic collection of electronic patient-reported outcome measures (ePROMs) in routine oncology clinical practice. Objective: This study aimed to assess compliance...
3.
Staehler M, Basso U, Eymard J, Barthelemy P, Bigot P, Laramas M, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102285.
PMID: 39740313
Background: There is a lack of published data on real-world cabozantinib use in patients with advanced renal cell carcinoma after prior vascular endothelial growth factor (VEGF)-targeted therapy. Methods: CASSIOPE was...
4.
Maiorano B, Catalano M, Mercinelli C, Roviello G, Maruzzo M, De Giorgi U, et al.
Clin Genitourin Cancer
. 2024 Nov;
23(1):102267.
PMID: 39603144
Introduction: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score is the most important prognostic score to stratify patients with metastatic renal cell carcinoma (mRCC), helping to guide treatment...
5.
Armstrong A, Clarke N, Oya M, Procopio G, de Menezes J, Guedes J, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39492050
PROpel (NCT03732820) was a positive phase 3 trial that demonstrated a clinically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in first-line metastatic castration-resistant...
6.
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo P, El Zarif T, McClure H, et al.
Clin Genitourin Cancer
. 2024 Oct;
22(6):102230.
PMID: 39461026
Background: Androgen receptor signalling inhibitors (ARSIs) abiraterone acetate (AA) enzalutamide (Enza), are currently the standard first-line (L1) treatments for metastatic castration-resistant prostate cancer (mCRPC), and docetaxel (D) is reserved as...
7.
Giunta E, Roviello G, Conteduca V, Verzoni E, Procopio G, De Giorgi U
Crit Rev Oncol Hematol
. 2024 Oct;
204:104534.
PMID: 39447667
The definition of "non-metastatic hormone-sensitive prostate cancer" (nmHSPC) can be applied to patients with prostate cancer (PC) who are androgen-deprivation therapy-naïve and without evidence of metastatic disease. This definition includes...
8.
Clarke N, Armstrong A, Oya M, Shore N, Procopio G, Guedes J, et al.
Eur Urol Oncol
. 2024 Oct;
PMID: 39384451
Background And Objective: In PROpel (NCT03732820), olaparib + abiraterone resulted in a statistically significant radiographic progression-free survival (rPFS) benefit and numerically prolonged overall survival (OS) versus placebo + abiraterone in...
9.
Rametta A, Ambrosini P, Cavalli C, Gusmaroli E, Claps M, Giannatempo P, et al.
Tumori
. 2024 Oct;
110(6):410-415.
PMID: 39370628
Genitourinary cancers present significant challenges to oncologists, necessitating innovative approaches for improved patient outcomes. The 'Controversies in Genitourinary Cancers' congress, held in January 2024, convened international experts to address the...
10.
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo P, Zanardi E, et al.
Clin Genitourin Cancer
. 2024 Aug;
22(5):102185.
PMID: 39217072
Background: Managing metastatic castration-resistant prostate cancer (mCRPC) in men aged ≥ 75 is challenging due to limited data. Regardless of age, in real-world clinical practice, most mCRPC still derive from...